Streamlining the complex process from sleep apnea diagnosis to treatment using digital health platforms meets the shared mission of addressing the growing and undermanaged sleep apnea epidemic
CAESAREA, Israel, April 6, 2020 — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today announced that it has entered into an agreement with Sleep Data Diagnostics and its virtual-care platform BetterNight and Sleep Data Holdings, a leading provider of home-based positive airway pressure (PAP) services. This agreement is designed to radically simplify the process by which both sleep and non-sleep referring physicians, such as cardiologists, can refer their patients for sleep apnea testing with WatchPAT®️ through Itamar Medical and BetterNight’s platforms providing a full care pathway that includes testing, medical consultation, continuous positive airway pressure (CPAP) therapy, billing and reimbursement channels. The agreement is expected to increase patient access to WatchPAT testing without the need to leave their homes and provide physicians, with a focus on cardiologists, and their patients, with information and interventions for managing sleep apnea and improving health outcomes.
Itamar Medical and BetterNight will collaborate to provide physicians and their patients a fully integrated and streamlined solution. Itamar Medical will provide patients suspected of having sleep apnea with a sleep apnea diagnostic study, facilitate a consultation with a board-certified physician for study interpretation and receipt of a prescription for a recommended therapy, if needed, enabled by its digital health platform. When elected by the managing physician, BetterNight will provide home-based CPAP therapy care using its advanced monitoring algorithm and remote respiratory therapy consultation and manage insurance coverage verification, preauthorization and billing.
“Physicians, particularly cardiologists, are aware of the negative effects sleep disordered breathing can have on their patients. However, they face a variety of hurdles to ensuring that patients undergo testing and receive appropriate treatment. This is even more challenging today due to the COVID-19 pandemic as so many patients must stay at home and access to in-lab testing is limited,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical. “This agreement demonstrates our commitment in working with leaders across the sleep apnea ecosystem to add home care options for sleep apnea management and addressing the global sleep apnea epidemic.”
It’s estimated that 60 million people in the United States have undiagnosed sleep apnea and, today, the standard care pathway includes multiple in-person visits to the limited number of sleep practices and Durable Medical Equipment offices resulting in almost 80% of those patients remaining undiagnosed. The integration of Itamar Medical’s digital home-based diagnostic platform with BetterNight’s ability to perform remote therapy set up and optimization is expected to enable sleep care management. This is accomplished by significantly improving the rate of conversion from diagnosis-to-treatment, achieving high long-term adherence rate while keeping patients at home satisfied, with only two weeks from referral to sleep apnea treatment.
“BetterNight is a leader in providing comprehensive sleep solutions that have the potential to make a positive impact on the millions of people living with sleep disorders. Adding WatchPAT’s innovative technology, as well as the Itamar Digital Health platform, will be a key component of our sleep apnea solution,” said Dave French, Chief Executive Officer of Sleep Data.
Dr. Dominic Munafo, Chief Medical Officer of BetterNight, said, “Sleep is vitally important to a patient’s health, restoring their immune system, lessening the impact of chronic disease and improving their ability to fight infection. It is crucial to pioneer safe and innovative ways to address the sleep health needs of patients during the COVID-19 pandemic. WatchPAT®️ ONE allows patients to access highly accurate and data-rich sleep apnea testing from the comfort of their homes, eliminating the barriers associated with overnight testing at a sleep clinic and reducing infection risk. Our sleep specialist staff uses multiple WatchPAT®️ signals to provide rapid and accurate diagnoses, allowing those patients who need CPAP therapy to receive their CPAP devices and coaching in a timely manner. We are excited to collaborate with Itamar Medical in bridging the gap between a cardiologist’s sleep study referral and effective therapy.”
About Itamar Medical Ltd.
Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.
BetterNight is the nation’s only comprehensive virtual-care sleep solution combining a clinically validated sleep assessment with a CBTi solution and a telehealth-based sleep apnea platform. Results include lower unit costs, superior adherence, improved patient satisfaction, and higher health outcomes. BetterNight’s parent company, Sleep Data, is a recognized leading provider of sleep services in the San Diego metropolitan region for 24 years. BetterNight’s mission is to have a positive impact on the lives of people living with sleep disorders by simplifying the complex process from diagnosis to treatment. Please visit www.betternight.com.
This Press Release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. For example, when we discuss an increase in the rate of conversion from diagnosis to treatment, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of the Company’s control and actual results, expressed or implied by such forward-looking statements, could differ materially from the Company’s current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by the Company in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”) and the Israel Securities Authority (“ISA”), including the Company’s latest Form 20-F and the Company’s final prospectus filed under Rule 424(b) on January 31, 2020, which are on file with the SEC and the ISA. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
The contents of any website of hyperlinks mentioned in this press release are for informational purposes only and the contents thereof are not part of this press release nor is it incorporated herein by reference.
Lazar FINN Partners
Eran Gabbai, Partner
Galbert-Kahana Investor Relations and Public Relations